News & Updates

RSV vaccination: Protecting older adults with comorbidities

Respiratory syncytial virus (RSV) infection in the elderly and older adults with comorbidities may lead to death or severe complications that require hospitalization. At an industry-sponsored symposium during the Advances in Medicine 2026 conference, Dr Ken Ka-Pang Chan of the Department of Medicine and Therapeutics, Chinese University of Hong Kong, discussed the role of vaccination and clinical impact of the recombinant adjuvanted RSVPreF3 vaccine, especially in adults with underlying high-risk conditions such as cardiovascular (CV) and metabolic disease, asthma, and chronic obstructive pulmonary disease (COPD).   

SMA treatment with risdiplam: Experience in HK

Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder that causes progressive muscle weakness and wasting, resulting in loss of motor function. The oral drug risdiplam demonstrated improvement or stabilization of motor function in clinical studies of patients with SMA. Professor Sophelia Chan of the Department of Paediatrics and Adolescent Medicine, University of Hong Kong, shared the latest published local findings on treatment outcomes with risdiplam in paediatric and adult patients with SMA.

HK cases: Aflibercept 8 mg achieves rapid disease control with extended treatment intervals in DME

A 54-year-old male with an 8-year history of type 2 diabetes (T2D; HbA_1c, 8 percent) reported blurred vision in the right eye (OD) on 5 June 2023. He was diagnosed with OD diabetic macular oe­dema (DME) and bilateral (OU) prolifera­tive diabetic retinopathy (PDR). 

Optimizing CKD care: Early detection and GDMT improve outcomes

Chronic kidney disease (CKD) is a noncommunicable disease with increasing importance. Its pathophysiology interacts with cardiovascular (CV) and metabolic diseases, and extends to other neurological and respiratory disorders with clinically significant interplay. Despite its growing global burden, CKD remains underdiagnosed and undertreated. At a symposium in Hong Kong, a multidisciplinary panel highlighted the urgent need for earlier identification of CKD, integrated CV-kidney-metabolic (CKM) care, and timely implementation of guideline-directed medical therapy (GDMT) — including sodium-glucose cotransporter-2 inhibitors (SGLT2i; eg, dapagliflozin) — to slow progression toward kidney failure and reduce CKD-related complications.

Addressing treatment complexity in CKD with early initiation of empagliflozin

Polypharmacy is a well-recognized challenge in chronic kidney disease (CKD) management, driving nonadherence and accelerating disease progression. In an interview with MIMS Doctor, Professor Takashi Yokoo of Jikei University, Japan, discussed how multifunctional sodium-glucose cotransporter-2 inhibitors (SGLT2i) help simplify treatment regimens based on his clinical experience with empagliflozin in patients with complex clinical profiles.

Optimizing frontline CLL therapy with next-generation BTKIs

Managing persistent symptomatic HFrEF with renal dysfunction using a soluble guanylate cyclase stimulator

An 82-year-old retired physician with multiple cardiovascular (CV) risk factors presented with heart failure (HF). His medical history included hypertension, diabetes mellitus, hy­perlipidaemia, and stage 4 chronic kidney disease (CKD) with estimat­ed glomerular filtration rate (eGFR) of 25 mL/min/1.73 m² and creatinine level of 350 μmol/L. Despite these comor­bidities, he was enjoying a good qual­ity of life and had recently been on a cruise. 

[VIDEO]: Achieving Enhanced Recovery After Surgery objectives with ropivacaine

Dr Shahridan Bin Mohd Fathil, Consultant Anaesthesiologist at Gleneagles Hospital Johor in Malaysia, discusses Enhanced Recovery After Surgery (ERAS) objectives and how ropivacaine helps achieve them, describes the types of anaesthesia he uses in daily practice, including those suitable for fast-track anaesthesia, and examines the advantages of peripheral nerve blocks (PNBs).

Use of sotatercept in a patient with transplant-ineligible PAH on dual therapy

This is a case of a 64-year-old woman with pulmonary arterial hyper­tension (PAH) poorly controlled on dual therapy, who was intolerant of selexi­pag and unsuitable for lung transplan­tation. 

[VIDEO]: Metastatic hormone-sensitive prostate cancer case series

Prof Axel Merseburger, Chairman of the Department of Urology at the University Hospital of Schleswig-Holstein in Lübeck, Germany, shares four metastatic hormone-sensitive prostate cancer (mHSPC) patient cases, discusses available treatment options and examines how individual characteristics determine optimal management.